Department of Dermatology, University of Florida College of Medicine, Gainesville, Florida, USA.
Department of Dermatology, University of Florida College of Medicine, Gainesville, Florida, USA.
Clin Dermatol. 2020 May-Jun;38(3):384-396. doi: 10.1016/j.clindermatol.2019.07.023. Epub 2019 Jul 26.
Rituximab is a monoclonal antibody targeting CD20 on B cells with proven efficacy for pemphigus vulgaris, now an FDA-approved indication. Other autoimmune bullous diseases can be challenging to treat and have significant associated morbidity and mortality, but data supporting the use of rituximab in pemphigoid group diseases remain limited. Although rituximab demonstrates efficacy for clinical improvement and remission in pemphigoid, concern for adverse events may also limit the use of this medication. We review the current evidence fo rthe use of rituximab in pemphigoid diseases, pertinent dosing schedules and laboratory monitoring, and the associated common and rare adverse events. Review of the literature to date not only supports consideration of rituximab for treatment of refractory pemphigoid group diseases but also reflects tolerability and an acceptable safety profile.
利妥昔单抗是一种针对 B 细胞表面 CD20 的单克隆抗体，已被证明对寻常型天疱疮有效，现已被 FDA 批准用于该适应证。其他自身免疫性大疱性疾病的治疗具有挑战性，且与之相关的发病率和死亡率较高，但支持利妥昔单抗用于大疱性类天疱疮疾病的应用的数据仍然有限。尽管利妥昔单抗在天疱疮的临床改善和缓解方面显示出疗效，但对不良事件的担忧也可能限制该药物的应用。我们回顾了利妥昔单抗在大疱性类天疱疮疾病中的应用的现有证据，包括相关的剂量方案和实验室监测，以及常见和罕见的不良事件。对现有文献的回顾不仅支持将利妥昔单抗考虑用于治疗难治性大疱性类天疱疮疾病，而且还反映了其耐受性和可接受的安全性。
